Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Chris H. Polman, Jerry S. Wolinsky, Stephen C. Reingold et al.|Annals of Neurology|2005Cited by 5k
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Christine Lebrun‐Frénay, Gilles Edan et al.|Neurology|2016Cited by 130
Ethics of placebo-controlled clinical trials in multiple sclerosisC. H. Polman, Jerry S. Wolinsky, Stephen C. Reingold et al.|Neurology|2008Cited by 73
Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeuticSimon Faissner, V. Wee Yong, Manoj K. Mishra et al.|Nature Communications|2017Cited by 65
Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?Simon Faissner, V. Wee Yong, Jennifer Hahn et al.|Multiple Sclerosis Journal|2017Cited by 37